皮肤治疗公司获得澳大利亚专利,为其每周的治疗提供了基础,为2026年非处方推出铺平了道路. Dermata Therapeutics gains Australian patent for its weekly acne treatment, paving the way for a 2026 OTC launch.

在获得美国先前的专利后,Dermata治疗公司在澳大利亚接受了使用其海绵技术进行下一代丙烷治疗的专利申请。 Dermata Therapeutics has received acceptance of its patent application in Australia for a next-generation acne treatment using its Spongilla technology, following a prior U.S. patent. 预计在2026年1月中旬获得的澳大利亚专利支持该公司计划在2026年中期推出每周一次,非处方的套件. The Australian patent, expected by mid-January 2026, supports the company’s plan to launch a once-weekly, over-the-counter acne kit in mid-2026. 治疗方法将Spongilla技术与OTC专著中的成分结合起来,旨在提高疗效和耐受性,同时减少副作用. The treatment combines Spongilla technology with an ingredient from the OTC monograph, aiming to improve effectiveness and tolerability while reducing side effects. 这家位于圣地亚哥的公司正在推进科学支持的OTC皮肤产品, 另外还有一些治疗方法正在开发中, 并且全球还有更多的专利申请待审. The company, based in San Diego, is advancing science-backed OTC dermatologic products, with additional treatments in development and further patent applications pending globally.